NSE: FABTECH · BSE: 544558 · ISIN INE0HF201011
Fabtech Technologies Limited stock analysis
Fabtech Technologies Limited ranks #1864 in the TickerSutra evidence-ranked universe with a score of 50/100 and 89% data confidence. The latest captured fundamentals show ROCE of 13.6%, quarterly sales growth of 10.3% and quarterly profit growth of 154.8%.Monitor only
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- Low debt/equity of 0.17×
- 28.4% three-year sales CAGR
- Institutional ownership is rising
- No promoter shares are reported as pledged
Risks and constraints
- CFO/EBITDA is below 0.6×
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹257cr | ₹32cr | ₹23cr | 12.0% |
| 2023 | ₹194cr | ₹25cr | ₹22cr | 13.0% |
| 2024 | ₹226cr | ₹35cr | ₹27cr | 15.0% |
| 2025 | ₹327cr | ₹39cr | ₹46cr | 12.0% |
| 2026 | ₹411cr | ₹35cr | ₹38cr | 9.0% |
| TTM | ₹418cr | ₹45cr | ₹49cr | 11.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
RoutineTrading WindowNSE · 26 Sept 2026 · Structured filingFabtech Technologies Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Fabtech Technologies Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Open original XBRL sourceIntimation of to be incorporated Step Down Subsidiary
RoutineOther RestructuringNSE · 25 Sept 2026Fabtech Technologies Limited has informed the Exchange about Other Restructuring- To be Incorporated Step Down Subsidiary
RoutineAcquisition of 'to be incorporated companies'-XBRLNSE · 25 Sept 2026 · Structured filingFABTECH TECHNOLOGIES LIMITED has informed the Exchange regarding Acquisition of to be incorporated companies
FABTECH TECHNOLOGIES LIMITED has informed the Exchange regarding Acquisition of to be incorporated companies
Open original XBRL sourceInteracting with the Investors / Analysts in Mumbai
MANAGEMENT COMMENTARY
Signals from filed documents
The size and sophistication of the projects underway provide clear evidence of our trajectory. We remain confident in our execution strength and a really long, long, long opportunity ahead, an unprecedented opportunity ahead. We thank you very much for being here with us, and...
Our focus is ensuring regulatory, confidence, compliant facilities across the pharmaceutical emerging markets and standing by our motto, which is making medicines affordable and available globally. Through the last three decades, we have built numerous facilities with WHOPQ approvals, EU GMP, US FDA, CGMP, and local regulatory approvals across the pharmaceutical emerging markets. Our attention to detail in the pharma
Our focus is ensuring regulatory, confidence, compliant facilities across the pharmaceutical emerging markets and standing by our motto, which is making medicines affordable and available globally. Through the last three decades, we have built numerous facilities with WHOPQ approvals, EU GMP, US FDA, CGMP, and local regulatory approvals across the pharmaceutical emerging markets. Our attention to detail in the pharma
With the in-house capabilities that Fabtech Technologies Limited has, the speed to market or the go-to-market timelines, are reduced. and the responsibility that we can take ensures that we are the reliable partner that is chosen by greenfield and brownfield entities. Our focus is ensuring regulatory, confidence, compliant facilities across the pharmaceutical emerging markets and standing by our motto, which is makin
It is important to note that order inflow has not slowed. The order book remains strong, pipeline visibility is healthy, and there have been no cancellations or pricing pressures. This clearly indicates that the Q3 impact is timing related, not demand related.
No, very, very less of domestic numbers, Maitri, here. We are largely export focused, the international market, the medicinal, the farm emerging market offers such a big potential that we rather focus on the geographies that are perceived to be a no- go area for many, and hence, when we have ring fenced the market in the last so many years, we would want to really reap in the benefits in the times to come. And each o
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…